Does the media refer more to CAH or COR?

In the previous week, Cencora had 6 more articles in the media than Cardinal Health. MarketBeat recorded 11 mentions for Cencora and 5 mentions for Cardinal Health. Cencora's average media sentiment score of 1.64 beat Cardinal Health's score of 0.41 indicating that Cencora is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cencora 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor COR or ELV?

In the previous week, Elevance Health had 7 more articles in the media than Cencora. MarketBeat recorded 18 mentions for Elevance Health and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat Elevance Health's score of 1.11 indicating that Cencora is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Elevance Health 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, COR or MCK?

McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cencora $321.33B 0.18 $1.55B $13.04 23.26 McKesson $403.43B 0.23 $4.76B $38.47 20.93

Is COR or MCK more profitable?

McKesson has a net margin of 1.18% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat McKesson's return on equity. Company Net Margins Return on Equity Return on Assets Cencora 0.78% 135.20% 4.20% McKesson 1.18% -345.35% 5.85%

Does the media refer more to COR or MCK?

In the previous week, McKesson had 14 more articles in the media than Cencora. MarketBeat recorded 25 mentions for McKesson and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat McKesson's score of 1.23 indicating that Cencora is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive McKesson 19 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, HSIC or COR?

Cencora has higher revenue and earnings than Henry Schein. Cencora is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Henry Schein $13.18B 0.73 $398M $3.31 25.50 Cencora $321.33B 0.18 $1.55B $13.04 23.26

Is HSIC or COR more profitable?

Henry Schein has a net margin of 2.95% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Henry Schein 2.95% 15.44% 5.53% Cencora 0.78% 135.20% 4.20%

Does the media refer more to HSIC or COR?

In the previous week, Cencora had 3 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Cencora and 8 mentions for Henry Schein. Cencora's average media sentiment score of 1.64 beat Henry Schein's score of 1.33 indicating that Cencora is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cencora 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, DHR or COR?

Danaher has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $24.57B 5.74 $3.61B $5.17 38.51 Cencora $321.33B 0.18 $1.55B $13.04 23.26

Is DHR or COR more profitable?

Danaher has a net margin of 14.89% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 14.89% 10.91% 6.94% Cencora 0.78% 135.20% 4.20%

Does the media prefer DHR or COR?

In the previous week, Danaher had 3 more articles in the media than Cencora. MarketBeat recorded 14 mentions for Danaher and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat Danaher's score of 1.23 indicating that Cencora is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Danaher 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Cencora 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Cencora (COR) Competitors

$303.31 +0.85 (+0.28%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$303.53 +0.22 (+0.07%)

As of 07/10/2026 08:00 PM Eastern

Compare

COR vs. CAH, ELV, MCK, HSIC, and DHR

Should you buy Cencora stock or one of its competitors? MarketBeat compares Cencora with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cencora include Cardinal Health (CAH), Elevance Health (ELV), McKesson (MCK), Henry Schein (HSIC), and Danaher (DHR). These companies are all part of the "medical" sector.

How does Cencora compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Cardinal Health has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$222.58B	0.25	$1.56B	$6.54	36.01
Cencora	$321.33B	0.18	$1.55B	$13.04	23.26

Cencora has a net margin of 0.78% compared to Cardinal Health's net margin of 0.62%. Cencora's return on equity of 135.20% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.62%	-92.61%	4.46%
Cencora	0.78%	135.20%	4.20%

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Cardinal Health pays out 31.5% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has increased its dividend for 29 consecutive years and Cencora has increased its dividend for 15 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cencora had 6 more articles in the media than Cardinal Health. MarketBeat recorded 11 mentions for Cencora and 5 mentions for Cardinal Health. Cencora's average media sentiment score of 1.64 beat Cardinal Health's score of 0.41 indicating that Cencora is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cencora	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cardinal Health presently has a consensus price target of $249.13, suggesting a potential upside of 5.77%. Cencora has a consensus price target of $367.75, suggesting a potential upside of 21.24%. Given Cencora's higher possible upside, analysts plainly believe Cencora is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83
Cencora	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73

Cardinal Health has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Cencora has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cencora beats Cardinal Health on 11 of the 19 factors compared between the two stocks.

How does Cencora compare to Elevance Health?

Cencora (NYSE:COR) and Elevance Health (NYSE:ELV) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

97.5% of Cencora shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 0.4% of Cencora shares are held by company insiders. Comparatively, 0.3% of Elevance Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elevance Health has lower revenue, but higher earnings than Cencora. Elevance Health is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$321.33B	0.18	$1.55B	$13.04	23.26
Elevance Health	$199.13B	0.45	$5.66B	$23.51	17.72

Elevance Health has a net margin of 2.62% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	0.78%	135.20%	4.20%
Elevance Health	2.62%	15.58%	5.57%

In the previous week, Elevance Health had 7 more articles in the media than Cencora. MarketBeat recorded 18 mentions for Elevance Health and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat Elevance Health's score of 1.11 indicating that Cencora is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cencora	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Elevance Health	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Elevance Health pays an annual dividend of $6.88 per share and has a dividend yield of 1.7%. Cencora pays out 18.4% of its earnings in the form of a dividend. Elevance Health pays out 29.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 15 consecutive years and Elevance Health has raised its dividend for 14 consecutive years.

Cencora presently has a consensus price target of $367.75, indicating a potential upside of 21.24%. Elevance Health has a consensus price target of $425.95, indicating a potential upside of 2.26%. Given Cencora's stronger consensus rating and higher possible upside, analysts clearly believe Cencora is more favorable than Elevance Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
Elevance Health	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.63

Cencora has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Elevance Health has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Summary

Cencora beats Elevance Health on 10 of the 19 factors compared between the two stocks.

How does Cencora compare to McKesson?

Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Cencora has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, McKesson has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 0.4% of Cencora shares are owned by insiders. Comparatively, 0.1% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$321.33B	0.18	$1.55B	$13.04	23.26
McKesson	$403.43B	0.23	$4.76B	$38.47	20.93

In the previous week, McKesson had 14 more articles in the media than Cencora. MarketBeat recorded 25 mentions for McKesson and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat McKesson's score of 1.23 indicating that Cencora is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cencora	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
McKesson	19 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. McKesson pays an annual dividend of $3.28 per share and has a dividend yield of 0.4%. Cencora pays out 18.4% of its earnings in the form of a dividend. McKesson pays out 8.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 15 consecutive years and McKesson has raised its dividend for 17 consecutive years.

Cencora currently has a consensus target price of $367.75, indicating a potential upside of 21.24%. McKesson has a consensus target price of $960.53, indicating a potential upside of 19.28%. Given Cencora's higher possible upside, research analysts plainly believe Cencora is more favorable than McKesson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
McKesson	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

McKesson has a net margin of 1.18% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat McKesson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	0.78%	135.20%	4.20%
McKesson	1.18%	-345.35%	5.85%

Summary

McKesson beats Cencora on 11 of the 19 factors compared between the two stocks.

How does Cencora compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Cencora (NYSE:COR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Cencora had 3 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Cencora and 8 mentions for Henry Schein. Cencora's average media sentiment score of 1.64 beat Henry Schein's score of 1.33 indicating that Cencora is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cencora	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 0.4% of Cencora shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Henry Schein has a net margin of 2.95% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Cencora	0.78%	135.20%	4.20%

Henry Schein has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Cencora has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Cencora has higher revenue and earnings than Henry Schein. Cencora is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.73	$398M	$3.31	25.50
Cencora	$321.33B	0.18	$1.55B	$13.04	23.26

Henry Schein presently has a consensus price target of $87.64, indicating a potential upside of 3.84%. Cencora has a consensus price target of $367.75, indicating a potential upside of 21.24%. Given Cencora's stronger consensus rating and higher possible upside, analysts plainly believe Cencora is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cencora	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Cencora beats Henry Schein on 10 of the 16 factors compared between the two stocks.

How does Cencora compare to Danaher?

Danaher (NYSE:DHR) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Danaher has a net margin of 14.89% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	14.89%	10.91%	6.94%
Cencora	0.78%	135.20%	4.20%

Danaher has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Cencora has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Danaher currently has a consensus price target of $231.64, indicating a potential upside of 16.34%. Cencora has a consensus price target of $367.75, indicating a potential upside of 21.24%. Given Cencora's higher probable upside, analysts plainly believe Cencora is more favorable than Danaher.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	1 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.79
Cencora	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.8%. Danaher pays out 30.9% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years and Cencora has increased its dividend for 15 consecutive years.

Danaher has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	5.74	$3.61B	$5.17	38.51
Cencora	$321.33B	0.18	$1.55B	$13.04	23.26

In the previous week, Danaher had 3 more articles in the media than Cencora. MarketBeat recorded 14 mentions for Danaher and 11 mentions for Cencora. Cencora's average media sentiment score of 1.64 beat Danaher's score of 1.23 indicating that Cencora is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Cencora	10 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

79.1% of Danaher shares are owned by institutional investors. Comparatively, 97.5% of Cencora shares are owned by institutional investors. 10.8% of Danaher shares are owned by insiders. Comparatively, 0.4% of Cencora shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Danaher beats Cencora on 12 of the 20 factors compared between the two stocks.

Get Cencora News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COR vs. The Competition

Export

Metric	Cencora	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$58.85B	$9.46B	$7.12B	$23.43B
Dividend Yield	0.79%	1.63%	2.68%	4.04%
P/E Ratio	23.26	25.73	27.22	31.27
Price / Sales	0.18	17.88	590.16	20.39
Price / Cash	14.00	114.05	49.34	25.05
Price / Book	33.66	6.05	10.90	4.77
Net Income	$1.55B	$177.20M	$3.57B	$1.07B
7 Day Performance	2.32%	-1.71%	-0.25%	-0.50%
1 Month Performance	7.60%	9.00%	5.77%	2.09%
1 Year Performance	2.79%	10.51%	28.14%	16.03%

Cencora Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COR Cencora	4.9828 of 5 stars	$303.31 +0.3%	$367.75 +21.2%	+2.0%	$58.85B	$321.33B	23.26	51,000	Positive News
CAH Cardinal Health	4.3746 of 5 stars	$236.40 -1.1%	$247.80 +4.8%	+45.4%	$55.37B	$222.58B	36.15	57,700	Analyst Forecast
ELV Elevance Health	4.6377 of 5 stars	$407.77 -2.4%	$419.16 +2.8%	+20.6%	$88.55B	$199.13B	17.34	97,100	Positive News Upcoming Earnings Analyst Forecast
MCK McKesson	4.9551 of 5 stars	$786.47 +0.0%	$960.53 +22.1%	+12.8%	$92.08B	$403.43B	20.44	43,000	Positive News Analyst Downgrade Insider Trade
HSIC Henry Schein	3.9956 of 5 stars	$86.57 +0.2%	$87.85 +1.5%	+13.2%	$9.87B	$13.18B	26.17	25,000	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:COR) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Competitors

COR vs. CAH, ELV, MCK, HSIC, and DHR

How does Cencora compare to Cardinal Health?

Summary

How does Cencora compare to Elevance Health?

Summary

How does Cencora compare to McKesson?

Summary

How does Cencora compare to Henry Schein?

Summary

How does Cencora compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COR vs. The Competition

Cencora Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cencora (COR) Competitors

COR vs. CAH, ELV, MCK, HSIC, and DHR

How does Cencora compare to Cardinal Health?

Which has better earnings and valuation, CAH or COR?

Is CAH or COR more profitable?

Is CAH or COR a better dividend stock?

Does the media refer more to CAH or COR?

Do analysts rate CAH or COR?

Which has more risk & volatility, CAH or COR?

Do institutionals and insiders believe in CAH or COR?

Summary

How does Cencora compare to Elevance Health?

Do insiders and institutionals believe in COR or ELV?

Which has preferable valuation & earnings, COR or ELV?

Is COR or ELV more profitable?

Does the media favor COR or ELV?

Is COR or ELV a better dividend stock?

Do analysts rate COR or ELV?

Which has more volatility and risk, COR or ELV?

Summary

How does Cencora compare to McKesson?

Which has more volatility and risk, COR or MCK?

Do insiders & institutionals believe in COR or MCK?

Which has higher earnings and valuation, COR or MCK?

Does the media refer more to COR or MCK?

Is COR or MCK a better dividend stock?

Do analysts rate COR or MCK?

Is COR or MCK more profitable?

Summary

How does Cencora compare to Henry Schein?

Does the media refer more to HSIC or COR?

Do institutionals and insiders believe in HSIC or COR?

Is HSIC or COR more profitable?

Which has more risk & volatility, HSIC or COR?

Which has preferable earnings and valuation, HSIC or COR?

Do analysts recommend HSIC or COR?

Summary

How does Cencora compare to Danaher?

Is DHR or COR more profitable?

Which has more risk & volatility, DHR or COR?

Do analysts recommend DHR or COR?

Is DHR or COR a better dividend stock?

Which has stronger earnings & valuation, DHR or COR?

Does the media prefer DHR or COR?

Do institutionals and insiders hold more shares of DHR or COR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COR vs. The Competition

Cencora Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools